Cost outcomes of potentially inappropriate prescribing (PIP) in middle-aged adults: a Delphi consensus and cross-sectional study (4 March 2022)

Summary

This article in the British Journal of Clinical Pharmacology aimed to calculate the medication costs of potentially inappropriate prescribing for middle-aged adults compare with the cost of consensus-validated, evidence-based, ‘adequate’ alternative prescribing scenarios. It used a Delphi consensus panel and cross-sectional study to examine primary care data of 55,880 patients aged 45-64 years old in South London.

The study found that duplicate drug classes was the most costly criterion for both PIP and alternative prescribing. It identified no substantial cost difference between adequate prescribing versus PIP and the authors recommend that future studies investigate the wider health economic costs of alternative prescribing, such as reducing hospital admissions.